$76.44+4.44 (+6.17%)
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.
Spyre Therapeutics, Inc. in the Healthcare sector is trading at $76.44 with a market capitalization of $6.4B. Wall Street consensus targets $96.07 (15 analysts), implying a +25.7% move over the next 12 months. The stock is currently near its 52-week high of $79.54, remaining 98.1% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin ...
Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating SPY072 across three rheumatic diseases.
Spyre Therapeutics Inc. (NASDAQ:SYRE) is one of the best high short interest stocks with highest upside potential. On May 5, Spyre Therapeutics reported a strong Q1 2026, supported by a public offering that resulted in $1.2 billion in pro forma cash, providing a financial runway into late 2029. While R&D expenses rose to $60.4 million [β¦]
Spyre Therapeutics recently amended its SPY003 license agreement with Paragon Therapeutics, expanding rights from solely inflammatory bowel disease to all therapeutic, prophylactic, palliative, and diagnostic uses, while keeping dosing restrictions outside inflammatory bowel disease in place until at least 2028 for combinations and 2030 for monotherapy. The amendment, which also includes earlier termination of some restrictions if a material transaction such as a change of control occurs,...
Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.
Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.